Lynx1 Capital Management

Lynx1 Capital Management is a Puerto Rico-based hedge fund manager founded in March 2020 by Dr. Weston Nichols. The firm specializes in investing in U.S. biotechnology and life sciences companies, with a long-biased equity strategy focused on high-growth opportunities within the biotech sector[5][6]. It manages discretionary assets of approximately $268–$279 million as of early 2025 and is known for significant positions in innovative biotech firms such as Alpine Immune Sciences, Bionomics Ltd., Merus NV, Stoke Therapeutics, and TScan Therapeutics[4][5][6][9]. The firm has demonstrated active engagement through direct investments and participation in financing rounds for clinical-stage biotechs[6][9].